Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3900 - Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care



Tumour Site

Breast Cancer


Ludwig Heesen


Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270


L. Heesen1, K. Frenzel1, S. Bolte2, V. Bukur3, M. Diken4, E. Derhovanessian5, S. Kreiter4, A. Kuhn6, K. Kühlcke7, M. Löwer8, H. Lindman9, S. Pascolo10, M. Schmidt11, A. Schneeweiss12, T. Sjöblom13, K. Thielemans14, L. Zitvogel15, Ö. Türeci16, U. Sahin17

Author affiliations

  • 1 Project Management, BioNTech AG, 55131 - Mainz/DE
  • 2 Clinical research, BioNTech AG, 55131 - Mainz/DE
  • 3 Genomics, BioNTech AG, 55131 - Mainz/DE
  • 4 Immunotherapies & Preclinical Research, BioNTech AG, 55131 - Mainz/DE
  • 5 Gxp Analytics, BioNTech AG, 55131 - Mainz/DE
  • 6 Rna Biochemistry & Manufacturing, BioNTech AG, 55131 - Mainz/DE
  • 7 Management, BioNTech IMFS, 55743 - Idar-Oberstein/DE
  • 8 Biomarker Development, TRON gGmbH, 55131 - Mainz/DE
  • 9 Department Of Oncology, University Hospital Uppsala Akademiska Sjukhuset, 751 85 - Uppsala/SE
  • 10 Urpp Translational Cancer Research, University of Zurich, Zurich/CH
  • 11 Klinik Und Poliklinik Für Geburtshilfe Und Frauengesundheit, Johannes Gutenberg-Universität Mainz, Mainz/DE
  • 12 Division Gynecologic Oncology/national Center For Tumor Diseases, University Hospital Heidelberg, 69115 - Heidelberg/DE
  • 13 Department Of Immunology, Uppsala University, Uppsala/SE
  • 14 Dep. Immunology-physiology, University Hospital Brussels, Brussels/BE
  • 15 -, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 16 Management, Cluster for Individualized Immune Intervention, 55131 - Mainz/DE
  • 17 Management, BioNTech AG, 55131 - Mainz/DE

Abstract 3900


Treatment of triple negative breast cancer (TNBC) is hampered by lack of established therapeutic targets like hormone receptors or HER-2. Surgery, chemotherapy and radiotherapy are the standard of care yet cure rates in patients with TNBC remain inferior compared to other BC subtypes. Approaches tailored to the patient’s individual tumor signature may lead to improvement. The “Mutanome Engineered RNA Immuno-Therapy (MERIT)” consortium is validating an innovative individualized mRNA-based vaccine for TNBC treatment. MERIT is a collaboration of 5 European partners (academia and industry) dedicated to realize a personalized approach for TNBC treatment. The consortium set up a clinical workflow covering drug development from target discovery and validation to GMP manufacturing and drug release for each individual patient (MUTANOME). Moreover, the consortium established a pre-synthesized mRNA vaccine warehouse containing the most frequently shared tumor-associated antigens (TAA) in TNBC for drug supply (WAREHOUSE).

Trial design

A phase I trial in 2 European countries assesses the feasibility, safety and biological efficacy of this personalized immunotherapy. TNBC patients (pT1cN0M0 – TxNxM0) after surgery and (neo-)adjuvant chemotherapy will be allocated to one of two study arms. Patients in ARM1 receive 8 WAREHOUSE vaccinations with personalized TAA combinations corresponding to the patient tumor’s antigen-expression profile. Patients in ARM2 are first treated with the WAREHOUSE approach followed by 8 vaccination cycles of an on-demand manufactured MUTANOME vaccine encoding the unique mutation signature of the individual patient identified by NGS. The mRNAs are administered intravenously as a RNA-lipoplex formulation which protects RNA from degradation, activates innate immunity, transfects APCs and consequently induces highly potent antigen-specific T-cell responses. Three clinical sites are open for recruitment; >12 patients were screened and vaccinations with WAREHOUSE or MUTANOME RNAs have started. We give insights into features of the established process and present first stratification data. MERIT was funded by the EU Commission’s FP7 and is led by BioNTech AG.

Clinical trial identification

EudraCT: 2014-002274-37.

Legal entity responsible for the study

BioNTech AG.


European Commission’s FP7; BioNTech AG.

Editorial Acknowledgement


L. Heesen, K. Frenzel, S. Bolte, V. Bukur, E. Derhovanessian, S. Kreiter, A. Kuhn: Employment: BioNTech. M. Diken: Patent ownership, patent applications, employment: BioNTech AG. K. Kühlcke: Employment: BioNTech IMFS. T. Sjöblom: Founder, board member, shareholder: ExScale Biopecimen Solutions. A. Ö. Türeci: Co-founder: Ganymed Pharmaceuticals GmbH. U. Sahin: Patent ownership, patent applications, stock owner, management board member, co-founder: BioNTech AG; Co-founder, chair: TRON gGmbH; Membership on advisory board, co-founder: Ganymed Pharmaceuticals GmbH. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.